
Sign up to save your podcasts
Or


💡 TARGET-FIRST trial (NEJM, Aug 2025) shows that in low-risk AMI patients post-PCI with complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy is noninferior to dual antiplatelet therapy—with 54% fewer bleeding events 🩸🛑💊
⚖️ A modern, patient-tailored antiplatelet strategy—backed by potent P2Y12 inhibitors and smart selection—might just be the new norm in contemporary cardiology 🫀
📘 New England Journal of Medicine
🔗 https://doi.org/10.1056/NEJMoa2508808
#Cardiology #DAPT #PrecisionMedicine #NEJM #TARGETFIRST
By Dr RR Baliga, MD, MBA5
66 ratings
💡 TARGET-FIRST trial (NEJM, Aug 2025) shows that in low-risk AMI patients post-PCI with complete revascularization, stopping aspirin after 1 month and continuing P2Y12 monotherapy is noninferior to dual antiplatelet therapy—with 54% fewer bleeding events 🩸🛑💊
⚖️ A modern, patient-tailored antiplatelet strategy—backed by potent P2Y12 inhibitors and smart selection—might just be the new norm in contemporary cardiology 🫀
📘 New England Journal of Medicine
🔗 https://doi.org/10.1056/NEJMoa2508808
#Cardiology #DAPT #PrecisionMedicine #NEJM #TARGETFIRST

907 Listeners

3,379 Listeners

20,662 Listeners